ICYMI: Alongside the IND clearance announcement, Tr1X also announced that it has received $50 million in venture financing. #MultipleSclerosis #celltherapy #Tregs Tr1X Read more: https://hubs.li/Q03PcD4v0
CGTLive
Online Audio and Video Media
Cranbury, New Jersey 3,194 followers
CGTLive™ delivers the latest news and expert insights on cell, gene, regenerative, and engineered medicines.
About us
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.
- Website
-
https://www.cgtlive.com/
External link for CGTLive
- Industry
- Online Audio and Video Media
- Company size
- 501-1,000 employees
- Headquarters
- Cranbury, New Jersey
- Type
- Privately Held
Locations
-
Primary
Get directions
2 Clarke Dr
Cranbury, New Jersey 08512, US
Updates
-
The trial’s second cohort is actively enrolling patients and the study is expected to include up to 14 patients in total. #LGMD #MuscularDystrophy #genetherapy AskBio Inc. Read more: https://hubs.li/Q03PcxKV0
-
ICYMI: KB801, which takes the form of a resodable eye drop, is currently being evaluated in the randomized, placebo-controlled phase 1/2 EMERALD-1 clinical trial. #NeurotrophicKeratitis #Keratitis #genetherapy Krystal Biotech, Inc. Read more: https://hubs.li/Q03Pb7BN0
-
ICYMI: ABO-503 uses a novel capsid referred to as AAV204 and is intended to deliver a functional copy of the human RS1 gene. #XLRS #genetherapy #retinoschisis Abeona Therapeutics Read more: https://hubs.li/Q03P2tB80
-
ICYMI: Data from a global phase 1/2 clinical trial supports the BLA. #LeukocyteAdhesionDeficiency #genetherapy #LADI Rocket Pharmaceuticals Read more: https://hubs.li/Q03P2wct0
-
The safety set presented at #ESGCT included 6 patients. #Gaucher #GaucherDisease #genetherapy Spur Therapeutics Read more: https://hubs.li/Q03P2w4Q0
-
Alongside the IND clearance announcement, Tr1X also announced that it has received $50 million in venture financing. #MultipleSclerosis #celltherapy #Tregs Tr1X Read more: https://hubs.li/Q03NRK5X0
-
ICYMI: Among 12 patients treated in the pivotal CHORD study, 11 patients displayed clinically meaningful improvements in hearing, with 3 of the patients showing normal hearing levels. #genetherapy #HearingLoss #Regeneron Regeneron Read more: https://hubs.li/Q03NR8b20
-
ICYMI: Myrtelle pointed out that ongoing follow-up and is continuing to show potential for a durable effect from the gene therapy treatment. #Canavan #CanavanDisease #genetherapy Read more: https://hubs.li/Q03NQkX90
-
KB801, which takes the form of a resodable eye drop, is currently being evaluated in the randomized, placebo-controlled phase 1/2 EMERALD-1 clinical trial. #NeurotrophicKeratitis #Keratitis #genetherapy Krystal Biotech, Inc. Read more: https://hubs.li/Q03NLTZf0